Secukinumab bests etanercept, placebo for sustained improvement of psoriasis

At least two-thirds of adults with plaque psoriasis treated with the fully human anti-interleukin-17A monoclonal antibody secukinumab achieved PASI 75 at 12 weeks in two related randomized phase III...